Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.

PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.

The conversation is about someone using finasteride and minoxidil along with microneedling as a treatment for hair loss, and there's a mention of scalp tattooing as an alternative or additional approach. Some responses mock the approach, while others inquire about the specifics of the treatment and its effectiveness.

Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.

The conversation is about using GHK-CU peptide for hair regrowth. Minoxidil, finasteride, and RU58841 are also mentioned as potential treatments for hair loss.

Zeuss sublingual products for hair loss, including finasteride and a finasteride-free option, are discussed for their potential to reduce side effects through sublingual delivery. The inclusion of copper peptides is noted, but the high price is a concern without more user feedback.

The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.

Users discuss the release of Pyrilutamide 1% outside China and its potential effectiveness compared to 0.5%. They also mention using Minoxidil, Finasteride, and RU58841 for hair loss treatment.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

The user is pleased with their hair transplant results but is concerned about the vertex area. They use Minoxidil and finasteride daily and had the procedure at a clinic in Athens.

The user is seeking advice on safe hair loss treatments for a household with pets, avoiding minoxidil due to its danger to cats. They are considering alternatives like dutasteride and looking for affordable options.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

Pyrilutamide 0.9% (kx-826) is available for shipping to Europe from Amazon US and Koshinemall. Shipping costs and availability vary between the two shops.

After 8 months of using oral Minoxidil 5mg and Finasteride 1mg, the user still experiences hair loss, particularly miniaturized hairs in the mid-scalp area, along with itching. They are concerned about losing around 40 hairs daily despite treatment.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The hair loss treatment Pyrilutamide and whether it has had any results for users. Martinsahara is planning to buy some soon.

Piroctone olamine is more effective than ketoconazole for increasing hair growth and reducing itching and dandruff. Treatments discussed include Minoxidil, finasteride, and RU58841.

A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user experienced side effects from spironolactone and is seeking alternatives for androgenetic alopecia (AGA), considering saw palmetto but unsure of its effectiveness. They are also exploring the possibility of using topical spironolactone, despite availability challenges.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

The user showed a one-year hair regrowth progress using finasteride only, after stopping minoxidil due to its toxicity to cats. They noticed hair growth around six or seven months into treatment.

Treatment for hair loss, including Pyrilutamide, Minoxidil, Finasteride, and RU58841; with some users reporting success in growing vellus hairs.

The user is discussing hair regrowth after 3.5 months of using finasteride, questioning if the new growth is baby hairs. They compare photos from December to the present to assess progress.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.

A user applied minoxidil for hair loss and worried about its toxicity to cats after their cat drank from a water fountain they touched. After consulting a vet and pet poison control, they were reassured that the exposure was not enough to harm the cat, and others advised using gloves and being cautious in the future.

The user is documenting their hair loss journey, using oral finasteride since January 2025, and plans to add microneedling and rosemary oil. They have experienced no further hair loss but no gains, and are considering oral minoxidil due to having pets.